Patrick Verheyen Net Worth

What's Patrick Verheyen's mailing address?

Patrick's mailing address filed with the SEC is C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON, MA, 02135.

Insiders trading at Cue Biopharma Inc

Over the last 7 years, insiders at Cue Biopharma Inc have traded over $1,426,672 worth of Cue Biopharma Inc stock and bought 1,194,685 units worth $5,848,356 . The most active insiders traders include Daniel R Passeri, Aaron G.L. Fletcher, and Barry J. Simon. On average, Cue Biopharma Inc executives and independent directors trade stock every 37 days with the average trade being worth of $18,162. The most recent stock trade was executed by Anish Suri on 25 August 2023, trading 4,000 units of CUE stock currently worth $11,040.

What does Cue Biopharma Inc do?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Cue Biopharma Inc executives and stock owners

Cue Biopharma Inc executives and other stock owners filed with the SEC include:

• Anish Suri,
  President, Chief Scientific Officer
• Daniel Passeri,
  Chief Executive Officer, Director
• Daniel R. Passeri M.Sc., MSc., J.D.,
  CEO & Director
• Colin Sandercock,
  Senior Vice President, General Counsel, Secretary
• Dr. Anish Suri Ph.D.,
  Pres & Chief Scientific Officer
• Kerri-Ann Millar,
  Chief Financial Officer
• Aaron Fletcher,
  Independent Director
• Barry Simon,
  Independent Director
• Peter Kiener,
  Independent Director
• Frederick Driscoll,
  Independent Director
• Frank Morich,
  Independent Chairman of the Board
• Cameron Gray,
  Independent Director
• Tamar Howson,
  Director
• Kenneth Pienta,
  Chief Medical Officer
• Kerri-Ann Millar,
  Chief Financial Officer
• Dr. Kenneth J. Pienta,
  Acting Chief Medical Officer
• Dr. Ronald D. Seidel III, Ph.D.,
  Co-Founder
• Dr. Matteo Levisetti M.D.,
  Sr. VP of Clinical Devel.
• Dr. Ronald D. Seidel III,
  Exec. VP and Head of R&D
• Colin G. Sandercock J.D., MSE,
  Sr. VP, Gen. Counsel & Sec.
• George B. Zavoico Ph.D.,
  VP of Investor Relations & Corp. Devel.
• Dr. Steven C. Almo,
  Co-Founder and Chairman of Scientific & Clinical Advisory Board
• Dr. Rodolfo J. Chaparro,
  Co-Founder & Sr. Advisor
• Bethany Mancilla,
  SVP and Chief Business Officer
• Ronald D. Iii Seidel,
  EVP, Head of R&D
• Christopher A Marlett,
  Director
• Anthony Digiandomenico,
  Director
• Rodolfo Chaparro,
  EVP, Head of Immunology
• Steven L Mcknight,
  Director
• Patricia Nasshorn,
  Chief Business Officer
• Matteo Levisetti,
  Chief Medical Officer
• Michael J Fox,
  
• Pamela Garzone,
  
• Patrick Verheyen,
  
• Lucinda Warren,
  CHIEF BUSINESS OFFICER